PMC10371012_01
Clinical manifestation of EBA in Case 2 before (top left) and after treatment (top right) and Case 3 before (bottom left) and after treatment (bottom right). Figures of Case 3 (bottom) show a wound caused by trauma - before treatment with rituximab, post-traumatic wounds healed significantly longer than after the treatment.
fimmu-14-1214011-g002.jpg
PMC10371012_02_fimmu-14-1214011-g002.jpg
f2
The patient has been in clinical remission for 2 years taking methylprednisone at a maintenance dose of 4 mg/d ( Figure 2 ).
PMC10371012_02
Clinical manifestation of EBA in Case 2 before (top left) and after treatment (top right) and Case 3 before (bottom left) and after treatment (bottom right). Figures of Case 3 (bottom) show a wound caused by trauma - before treatment with rituximab, post-traumatic wounds healed significantly longer than after the treatment.
fimmu-14-1214011-g002.jpg
PMC10371012_02_fimmu-14-1214011-g002.jpg
f2
The patient has been in clinical remission for 2 years taking methylprednisone at a maintenance dose of 4 mg/d ( Figure 2 ).
PMC10371012_03
Clinical manifestation of EBA in Case 1 before (left) and after treatment (right).
fimmu-14-1214011-g001.jpg
PMC10371012_03_fimmu-14-1214011-g001.jpg
f1
Direct immunofluorescence test revealed linear deposits of IgG and IgA within the BMZ ( Supplementary Figure 1 ).
Clinical manifestation of EBA in Case 4 before (left) and after treatment (right).
fimmu-14-1214011-g003.jpg
PMC10371012_03_fimmu-14-1214011-g003.jpg
f3
Skin wounds were healing at a faster rate compared to the patient's condition before biological therapy ( Figure 3 ).